BLAC vs. HSCS, SSKN, LFWD, STRR, LUCY, AMIX, STSS, QNRX, CHEK, and PTHL
Should you be buying Bellevue Life Sciences Acquisition stock or one of its competitors? The main competitors of Bellevue Life Sciences Acquisition include HeartSciences (HSCS), Strata Skin Sciences (SSKN), Lifeward (LFWD), Star Equity (STRR), Innovative Eyewear (LUCY), Autonomix Medical (AMIX), Sharps Technology (STSS), Quoin Pharmaceuticals (QNRX), Check-Cap (CHEK), and Pheton (PTHL). These companies are all part of the "medical equipment" industry.
Bellevue Life Sciences Acquisition vs. Its Competitors
Bellevue Life Sciences Acquisition (NASDAQ:BLAC) and HeartSciences (NASDAQ:HSCS) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.
55.3% of Bellevue Life Sciences Acquisition shares are held by institutional investors. Comparatively, 17.2% of HeartSciences shares are held by institutional investors. 33.7% of Bellevue Life Sciences Acquisition shares are held by company insiders. Comparatively, 1.8% of HeartSciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, HeartSciences had 1 more articles in the media than Bellevue Life Sciences Acquisition. MarketBeat recorded 1 mentions for HeartSciences and 0 mentions for Bellevue Life Sciences Acquisition. HeartSciences' average media sentiment score of 1.88 beat Bellevue Life Sciences Acquisition's score of 0.00 indicating that HeartSciences is being referred to more favorably in the news media.
HeartSciences has a consensus target price of $13.00, suggesting a potential upside of 281.23%. Given HeartSciences' stronger consensus rating and higher probable upside, analysts clearly believe HeartSciences is more favorable than Bellevue Life Sciences Acquisition.
Bellevue Life Sciences Acquisition has a beta of -0.08, suggesting that its share price is 108% less volatile than the S&P 500. Comparatively, HeartSciences has a beta of 2.56, suggesting that its share price is 156% more volatile than the S&P 500.
Bellevue Life Sciences Acquisition's return on equity of 0.00% beat HeartSciences' return on equity.
Summary
HeartSciences beats Bellevue Life Sciences Acquisition on 6 of the 10 factors compared between the two stocks.
Get Bellevue Life Sciences Acquisition News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLAC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BLAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bellevue Life Sciences Acquisition Competitors List
Related Companies and Tools
This page (NASDAQ:BLAC) was last updated on 9/1/2025 by MarketBeat.com Staff
